Position in NGNE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$4,463,384
+$4,330,481 QoQ
Shares Held
141,920
+1750.6% QoQ
Ownership
0.709%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#24
of 111 holders
Holding Since
Sep 2023
5 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Derivatives in NGNE
reported options exposure · as of Mar 31, 2025CallValue
$0
CallShares
0
PutValue
$2,342,000
PutShares
200,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Point72 Asset Management, L.P. holds $2,243,273,342 across 172 Biotechnology names. NGNE ranks #82 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
4,473,478 | $158,316,386 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,587,712 | $135,257,185 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,525,782 | $113,640,243 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
416,516 | $101,950,621 | |
| 5 | LEGN |
Legend Biotech Corp
|
3,076,124 | $88,838,461 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
137,029 | $73,577,721 | |
| 7 | CELC |
Celcuity Inc.
|
650,916 | $68,098,831 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
2,433,168 | $61,559,150 |
All Filings in NGNE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,463,384 | 141,920 | Shares | Defined | 2026-08-14 | |
| 2025-09-30 | $132,903 | 7,669 | Shares | Defined | 2025-11-14 | |
| 2025-03-31 | $2,342,000 | 200,000 | Put | Defined | 2025-07-21 | |
| 2024-03-31 | $1,426,879 | 28,033 | Shares | Defined | 2024-05-15 | |
| 2023-09-30 NLTX | — | 27,335 | Shares | Defined | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||